Filgrastim Hospira (US) + U.S.-approved Neupogen®

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Neutropenia (Low White Blood Cell Count)

Conditions

Neutropenia (Low White Blood Cell Count)

Trial Timeline

Mar 1, 2016 → Jun 1, 2016

NCT ID

NCT02766634

About Filgrastim Hospira (US) + U.S.-approved Neupogen®

Filgrastim Hospira (US) + U.S.-approved Neupogen® is a phase 1 stage product being developed by Pfizer for Neutropenia (Low White Blood Cell Count). The current trial status is completed. This product is registered under clinical trial identifier NCT02766634. Target conditions include Neutropenia (Low White Blood Cell Count).

What happened to similar drugs?

8 of 18 similar drugs in Neutropenia (Low White Blood Cell Count) were approved

Approved (8) Terminated (5) Active (8)

✅MicafunginAstellas PharmaApproved

✅Imipenem + ImipenemMerckApproved

✅Ceftolozane-Tazobactam + MeropenemMerckApproved

✅Ceftolozane-tazobactam IVMerckApproved

✅Neulasta (pegfilgrastim)AmgenApproved

✅Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)Gilead SciencesApproved

✅FilgrastimSandoz GroupApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02766634	Phase 1	Completed	Mar 1, 2016	Jun 1, 2016	Neutropenia (Low White Blood Cell Count)

Competing Products

20 competing products in Neutropenia (Low White Blood Cell Count)

See all competitors

Product	Company	Stage	Hype Score
Micafungin	Astellas Pharma	Approved	39
pegfilgrastim	Kyowa Kirin	Phase 2	35
HHPG-19K Injection	Jiangsu Hengrui Medicine	Phase 3	32
caspofungin acetate + Comparator: AmBisome	Merck	Phase 2	35
Imipenem + Imipenem	Merck	Approved	43
Posaconazole IV solution + Posaconazole powder for oral suspension	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Approved	50
Ceftolozane-tazobactam IV	Merck	Approved	35
Daptomycin + Daptomycin	Merck	Phase 3	32
pegfilgrastim	Amgen	Phase 3	40
Neulasta (pegfilgrastim)	Amgen	Approved	43
Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®)	Gilead Sciences	Approved	35
Filgrastim Hospira (US) + US-approved Neupogen®	Pfizer	Phase 1	29
HSP-130 + US-approved Neulasta + EU-approved Neulasta	Pfizer	Phase 1	29
linezolid + vancomycin	Pfizer	Phase 3	40
Anidulafungin	Pfizer	Phase 1/2	32
Nivestim®	Pfizer	Pre-clinical	18
Antibacterial agent for the treatment of febrile neutropenia	Pfizer	Pre-clinical	26
Voriconazole	Pfizer	Phase 1/2	32
ciprofloxacin + cefepime	Bayer	Phase 3	37